APO Research
Talk to an analyst

APO RESEARCH · REPORT

Monoclonal Antibody Biologics and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Monoclonal Antibody Biologics and Biosimilars Market Analysis and Forecast 2026-2032

21 December 2025195 pages

Choose your research edition.

Industry ResearchMonoclonal Antibody Biologics and Biosimilars Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Monoclonal Antibody Biologics and Biosimilars Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Monoclonal Antibody Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Monoclonal Antibody Biologics and Biosimilars Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Monoclonal Antibody Biologics and Biosimilars Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Monoclonal Antibody Biologics and Biosimilars market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Monoclonal Antibody Biologics and Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Monoclonal Antibody Biologics and Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Monoclonal Antibody Biologics and Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Monoclonal Antibody Biologics and Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Monoclonal Antibody Biologics and Biosimilars include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Biogen and Amgen, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Monoclonal Antibody Biologics and Biosimilars, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Monoclonal Antibody Biologics and Biosimilars, also provides the revenue of main regions and countries. Of the upcoming market potential for Monoclonal Antibody Biologics and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Monoclonal Antibody Biologics and Biosimilars revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Monoclonal Antibody Biologics and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Monoclonal Antibody Biologics and Biosimilars revenue, projected growth trends, production technology, application and end-user industry.

Monoclonal Antibody Biologics and Biosimilars Segment by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Roche

Eli Lilly

Pfizer

Biogen

Amgen

AbbVie

Sobi

Innovent Biologics

Celltrion

3SBIO

Monoclonal Antibody Biologics and Biosimilars Segment by Type

Biologics

Biosimilars

Monoclonal Antibody Biologics and Biosimilars Segment by Application

Cancer

Autoimmune Disease

Other

Monoclonal Antibody Biologics and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monoclonal Antibody Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Monoclonal Antibody Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monoclonal Antibody Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Monoclonal Antibody Biologics and Biosimilars in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Monoclonal Antibody Biologics and Biosimilars company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Monoclonal Antibody Biologics and Biosimilars revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Biologics Major Player Table 3. Biosimilars Major Player Table 4. Global Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Cancer Major Player Table 6. Autoimmune Disease Major Player Table 7. Other Major Player Table 8. Monoclonal Antibody Biologics and Biosimilars Industry Trends Table 9. Monoclonal Antibody Biologics and Biosimilars Industry Drivers Table 10. Monoclonal Antibody Biologics and Biosimilars Industry Opportunities and Challenges Table 11. Monoclonal Antibody Biologics and Biosimilars Industry Restraints Table 12. Global Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Monoclonal Antibody Biologics and Biosimilars Market Share by Region (2021-2026) Table 15. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Monoclonal Antibody Biologics and Biosimilars Market Share by Region (2027-2032) Table 17. Global Monoclonal Antibody Biologics and Biosimilars Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Players (2021-2026) Table 19. Global Monoclonal Antibody Biologics and Biosimilars Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Monoclonal Antibody Biologics and Biosimilars Key Players Headquarters & Area Served Table 21. Global Monoclonal Antibody Biologics and Biosimilars Players, Product Type & Application Table 22. Global Monoclonal Antibody Biologics and Biosimilars Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Monoclonal Antibody Biologics and Biosimilars by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Monoclonal Antibody Biologics and Biosimilars Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Type (2021-2026) Table 29. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Type (2027-2032) Table 30. Global Monoclonal Antibody Biologics and Biosimilars Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Application (2021-2026) Table 34. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Application (2027-2032) Table 35. Sanofi Company Information Table 36. Sanofi Business Overview Table 37. Sanofi Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Sanofi Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 39. Sanofi Recent Development Table 40. Johnson & Johnson Company Information Table 41. Johnson & Johnson Business Overview Table 42. Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 44. Johnson & Johnson Recent Development Table 45. Novartis Company Information Table 46. Novartis Business Overview Table 47. Novartis Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Novartis Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 49. Novartis Recent Development Table 50. Merck Company Information Table 51. Merck Business Overview Table 52. Merck Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Merck Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 54. Merck Recent Development Table 55. Roche Company Information Table 56. Roche Business Overview Table 57. Roche Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Roche Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 59. Roche Recent Development Table 60. Eli Lilly Company Information Table 61. Eli Lilly Business Overview Table 62. Eli Lilly Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Eli Lilly Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 64. Eli Lilly Recent Development Table 65. Pfizer Company Information Table 66. Pfizer Business Overview Table 67. Pfizer Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Pfizer Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 69. Pfizer Recent Development Table 70. Biogen Company Information Table 71. Biogen Business Overview Table 72. Biogen Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Biogen Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 74. Biogen Recent Development Table 75. Amgen Company Information Table 76. Amgen Business Overview Table 77. Amgen Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Amgen Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 79. Amgen Recent Development Table 80. AbbVie Company Information Table 81. AbbVie Business Overview Table 82. AbbVie Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. AbbVie Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 84. AbbVie Recent Development Table 85. Sobi Company Information Table 86. Sobi Business Overview Table 87. Sobi Monoclonal Antibody Biologics and Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Sobi Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 89. Sobi Recent Development Table 90. Innovent Biologics Company Information Table 91. Innovent Biologics Business Overview Table 92. Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 94. Innovent Biologics Recent Development Table 95. Celltrion Company Information Table 96. Celltrion Business Overview Table 97. Celltrion Monoclonal Antibody Biologics and Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Celltrion Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 99. Celltrion Recent Development Table 100. 3SBIO Company Information Table 101. 3SBIO Business Overview Table 102. 3SBIO Monoclonal Antibody Biologics and Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. 3SBIO Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 104. 3SBIO Recent Development Table 105. North America Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 106. North America Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 107. North America Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 108. North America Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 109. North America Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. North America Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 111. North America Monoclonal Antibody Biologics and Biosimilars Revenue by Country (US$ Million) & (2027-2032) Table 112. Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 113. Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 114. Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 115. Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 116. Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 118. Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Country (US$ Million) & (2027-2032) Table 119. China Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 120. China Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 121. China Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 122. China Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 123. Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 124. Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 125. Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 126. Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 127. Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Region (US$ Million) & (2021-2026) Table 129. Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Region (US$ Million) & (2027-2032) Table 130. SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 131. SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 132. SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 133. SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 134. SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 136. SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Country (US$ Million) & (2027-2032) Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Monoclonal Antibody Biologics and Biosimilars Image Figure 2. Global Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Monoclonal Antibody Biologics and Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 4. Biologics Image Figure 5. Biosimilars Image Figure 6. Global Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Monoclonal Antibody Biologics and Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 8. Cancer Image Figure 9. Autoimmune Disease Image Figure 10. Other Image Figure 11. Global Monoclonal Antibody Biologics and Biosimilars Market Size (US$ Million) & (2021-2032) Figure 12. Global Monoclonal Antibody Biologics and Biosimilars Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Monoclonal Antibody Biologics and Biosimilars Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Monoclonal Antibody Biologics and Biosimilars Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Type (2021-2032) Figure 19. Global Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Application (2021-2032) Figure 22. North America Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Monoclonal Antibody Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 24. North America Monoclonal Antibody Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 25. North America Monoclonal Antibody Biologics and Biosimilars Revenue Share by Country (2021-2032) Figure 26. United States Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Monoclonal Antibody Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 31. Europe Monoclonal Antibody Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 32. Europe Monoclonal Antibody Biologics and Biosimilars Revenue Share by Country (2021-2032) Figure 33. Germany Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Monoclonal Antibody Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 43. China Monoclonal Antibody Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 44. Asia Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Monoclonal Antibody Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 46. Asia Monoclonal Antibody Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 47. Asia Monoclonal Antibody Biologics and Biosimilars Revenue Share by Region (2021-2032) Figure 48. Japan Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 56. SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 57. SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue Share by Country (2021-2032) Figure 58. Brazil Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Monoclonal Antibody Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Biologics
  • Biosimilars
Applications
  • Cancer
  • Autoimmune Disease
  • Other
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Biogen
  • Amgen
  • AbbVie
  • Sobi
  • Innovent Biologics
  • Celltrion
  • 3SBIO

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Monoclonal Antibody Biologics and Biosimilars Market by Type
  3. 1.2.1 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Biologics
  5. 1.2.3 Biosimilars
  6. 1.3 Monoclonal Antibody Biologics and Biosimilars Market by Application
  7. 1.3.1 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Cancer
  9. 1.3.3 Autoimmune Disease
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Monoclonal Antibody Biologics and Biosimilars Market Dynamics
  1. 2.1 Monoclonal Antibody Biologics and Biosimilars Industry Trends
  2. 2.2 Monoclonal Antibody Biologics and Biosimilars Industry Drivers
  3. 2.3 Monoclonal Antibody Biologics and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Monoclonal Antibody Biologics and Biosimilars Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Monoclonal Antibody Biologics and Biosimilars Market Perspective (2021-2032)
  2. 3.2 Global Monoclonal Antibody Biologics and Biosimilars Growth Trends by Region
  3. 3.2.1 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Region (2021-2026)
  5. 3.2.3 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Monoclonal Antibody Biologics and Biosimilars Revenue by Players
  2. 4.1.1 Global Monoclonal Antibody Biologics and Biosimilars Revenue by Players (2021-2026)
  3. 4.1.2 Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Monoclonal Antibody Biologics and Biosimilars Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Monoclonal Antibody Biologics and Biosimilars Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Monoclonal Antibody Biologics and Biosimilars Key Players Headquarters & Area Served
  7. 4.4 Global Monoclonal Antibody Biologics and Biosimilars Players, Product Type & Application
  8. 4.5 Global Monoclonal Antibody Biologics and Biosimilars Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Monoclonal Antibody Biologics and Biosimilars Market CR5 and HHI
  11. 4.6.3 2025 Monoclonal Antibody Biologics and Biosimilars Tier 1, Tier 2, and Tier 3
5 Monoclonal Antibody Biologics and Biosimilars Market Size by Type
  1. 5.1 Global Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 5.3 Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Type (2021-2032)
6 Monoclonal Antibody Biologics and Biosimilars Market Size by Application
  1. 6.1 Global Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2032)
  3. 6.3 Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Merck
  20. 7.4.1 Merck Company Information
  21. 7.4.2 Merck Business Overview
  22. 7.4.3 Merck Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Merck Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  24. 7.4.5 Merck Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Roche Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Eli Lilly
  32. 7.6.1 Eli Lilly Company Information
  33. 7.6.2 Eli Lilly Business Overview
  34. 7.6.3 Eli Lilly Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Eli Lilly Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  36. 7.6.5 Eli Lilly Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 Biogen
  44. 7.8.1 Biogen Company Information
  45. 7.8.2 Biogen Business Overview
  46. 7.8.3 Biogen Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Biogen Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  48. 7.8.5 Biogen Recent Developments
  49. 7.9 Amgen
  50. 7.9.1 Amgen Company Information
  51. 7.9.2 Amgen Business Overview
  52. 7.9.3 Amgen Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Amgen Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  54. 7.9.5 Amgen Recent Developments
  55. 7.10 AbbVie
  56. 7.10.1 AbbVie Company Information
  57. 7.10.2 AbbVie Business Overview
  58. 7.10.3 AbbVie Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  59. 7.10.4 AbbVie Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  60. 7.10.5 AbbVie Recent Developments
  61. 7.11 Sobi
  62. 7.11.1 Sobi Company Information
  63. 7.11.2 Sobi Business Overview
  64. 7.11.3 Sobi Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Sobi Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  66. 7.11.5 Sobi Recent Developments
  67. 7.12 Innovent Biologics
  68. 7.12.1 Innovent Biologics Company Information
  69. 7.12.2 Innovent Biologics Business Overview
  70. 7.12.3 Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  72. 7.12.5 Innovent Biologics Recent Developments
  73. 7.13 Celltrion
  74. 7.13.1 Celltrion Company Information
  75. 7.13.2 Celltrion Business Overview
  76. 7.13.3 Celltrion Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Celltrion Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  78. 7.13.5 Celltrion Recent Developments
  79. 7.14 3SBIO
  80. 7.14.1 3SBIO Company Information
  81. 7.14.2 3SBIO Business Overview
  82. 7.14.3 3SBIO Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  83. 7.14.4 3SBIO Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  84. 7.14.5 3SBIO Recent Developments
8 North America
  1. 8.1 North America Monoclonal Antibody Biologics and Biosimilars Revenue (2021-2032)
  2. 8.2 North America Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 8.2.1 North America Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2026)
  4. 8.2.2 North America Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2027-2032)
  5. 8.3 North America Monoclonal Antibody Biologics and Biosimilars Revenue Share by Type (2021-2032)
  6. 8.4 North America Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 8.4.1 North America Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2026)
  8. 8.4.2 North America Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2027-2032)
  9. 8.5 North America Monoclonal Antibody Biologics and Biosimilars Revenue Share by Application (2021-2032)
  10. 8.6 North America Monoclonal Antibody Biologics and Biosimilars Revenue by Country
  11. 8.6.1 North America Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2021-2026)
  13. 8.6.3 North America Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Monoclonal Antibody Biologics and Biosimilars Revenue (2021-2032)
  2. 9.2 Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 9.2.1 Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2026)
  4. 9.2.2 Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2027-2032)
  5. 9.3 Europe Monoclonal Antibody Biologics and Biosimilars Revenue Share by Type (2021-2032)
  6. 9.4 Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 9.4.1 Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2026)
  8. 9.4.2 Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2027-2032)
  9. 9.5 Europe Monoclonal Antibody Biologics and Biosimilars Revenue Share by Application (2021-2032)
  10. 9.6 Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Country
  11. 9.6.1 Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2021-2026)
  13. 9.6.3 Europe Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Monoclonal Antibody Biologics and Biosimilars Revenue (2021-2032)
  2. 10.2 China Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 10.2.1 China Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2026)
  4. 10.2.2 China Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2027-2032)
  5. 10.3 China Monoclonal Antibody Biologics and Biosimilars Revenue Share by Type (2021-2032)
  6. 10.4 China Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 10.4.1 China Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2026)
  8. 10.4.2 China Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2027-2032)
  9. 10.5 China Monoclonal Antibody Biologics and Biosimilars Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Monoclonal Antibody Biologics and Biosimilars Revenue (2021-2032)
  2. 11.2 Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 11.2.1 Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2026)
  4. 11.2.2 Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2027-2032)
  5. 11.3 Asia Monoclonal Antibody Biologics and Biosimilars Revenue Share by Type (2021-2032)
  6. 11.4 Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 11.4.1 Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2026)
  8. 11.4.2 Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2027-2032)
  9. 11.5 Asia Monoclonal Antibody Biologics and Biosimilars Revenue Share by Application (2021-2032)
  10. 11.6 Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Country
  11. 11.6.1 Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2021-2026)
  13. 11.6.3 Asia Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue (2021-2032)
  2. 12.2 SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Type (2027-2032)
  5. 12.3 SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Application (2027-2032)
  9. 12.5 SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Country
  11. 12.6.1 SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Monoclonal Antibody Biologics and Biosimilars Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst